Immunovant (NASDAQ:IMVT) Receives Buy Rating from HC Wainwright

On March 22nd, 2025, HC Wainwright reaffirmed a buy rating for Immunovant (NASDAQ:IMVT – Free Report) in a report shared on Wednesday morning, as reported by Benzinga. The firm has set a target price of $51.00 on the company's stock.

Several other equity research analysts have also recently provided their insights on Immunovant. For instance, on January 15th, Bank of America lowered its price target for Immunovant shares from $48.00 to $45.00 while maintaining a buy rating. In a report dated March 4th, Cantor Fitzgerald upgraded Immunovant's rating to a strong buy. Furthermore, Wells Fargo & Company also cut their price target from $47.00 to $45.00, keeping an overweight rating on the stock in their note from December 19th. On March 10th, Guggenheim reiterated its buy rating for Immunovant shares, while Wolfe Research downgraded the stock from outperform to peer perform on January 3rd. In total, one analyst has assigned a hold rating, nine have rated it as a buy, and one analyst has given it a strong buy rating. According to data from MarketBeat.com, the consensus rating for Immunovant is currently a buy with an average target price of $41.70.

Immunovant Stock Overview

As of Wednesday, Immunovant shares opened at $19.64. The stock has reached a low of $17.01 and a high of $34.47 over the past year. Immunovant boasts a market capitalization of approximately $3.34 billion and a price-to-earnings ratio of -7.50, with a beta of 0.68. It also has a 50-day moving average of $20.86 and a 200-day moving average of $25.71.

Immunovant last posted its quarterly earnings results on February 10th, reporting earnings per share of ($0.76), which fell short of analysts’ expectations of ($0.68) by $0.08. Analysts predict that Immunovant will report an EPS of -2.69 for the current fiscal year.

Insider Transactions

In recent insider trading, director Andrew J. Fromkin sold 8,000 shares of the company on March 7th for an average price of $19.60, totaling $156,800. This transaction reduced his ownership stake by 8.01%, leaving him with about 91,913 shares valued at $1,801,494.80. Additionally, CEO Peter Salzmann sold 5,105 shares on January 8th at an average price of $24.10, worth approximately $123,030.50. Post-sale, the CEO holds 972,992 shares valued at $23,449,107.20, which reflects a slight decrease of 0.52% in his holding. The total number of company shares sold by insiders recently amounts to 35,510, valued at approximately $813,686, with insiders holding around 5.90% of the total stock.

Institutional Investor Involvement

Institutional investors have also been active with Immunovant stock. GF Fund Management CO. LTD. acquired a new stake valued at $76,000 in the fourth quarter. During the same period, Two Seas Capital LP increased its position by 123.4%, now owning 1,511,614 shares worth $37,443,000 after buying an additional 835,000 shares. Other firms, including Vestal Point Capital LP and Twinbeech Capital LP, have also added positions in Immunovant during the last quarter. Currently, approximately 47.08% of the stock is held by institutional investors and hedge funds.

About Immunovant

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies aimed at treating autoimmune diseases. The company’s lead product, batoclimab, is a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor and is under development to address conditions such as myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves' disease, and warm autoimmune hemolytic anemia.

Immunovant, Stock, Investment, Analyst, Market